{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1047.379","meta":{"versionId":"17","lastUpdated":"2016-12-27T01:00:03.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"Oncology Nursing Society Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2016-12-27"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1047.379","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113762.1.4.1047.379"}],"version":"20161227","name":"ModerateEmeticRiskCancerMedicationMethotrexate","title":"Moderate Emetic Risk Cancer Medication methotrexate","status":"active","experimental":false,"date":"2016-12-27T01:00:03-05:00","publisher":"Oncology Nursing Society Steward","description":"ONS measure set","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: NCCN Classification of chemotherapeutic medication),(Data Element Scope: This data element maps to the Assessment category of the QDM.),(Inclusion Criteria: Includes methotrexate  prescribable ingredient. Value ranges  for methotrexate =>250mg/m2 specified using MAT tool),(Exclusion Criteria: Excluded are codes not meeting inclusion criteria)","compose":{"include":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","concept":[{"code":"6851","display":"Methotrexate"}]}]},"expansion":{"identifier":"urn:uuid:9bac4bf2-5919-4798-8810-6bc2b4853cc6","timestamp":"2023-12-10T20:54:16-05:00","total":1,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"6851","display":"methotrexate"}]}}